source
- Actimed regains full rights to S-oxprenolol, ends $126 million Faraday licensing dealActimed Therapeutics announced it has reclaimed all worldwide rights to its experimental wasting disease drug S-oxprenolol, terminating the licensing agreement it had with Faraday Pharmaceuticals.…
- Tiziana Life Sciences CEO Ivor Elrifi boosts stake, buying 321,423 shares at $1 eachTiziana Life Sciences announced that its chief executive officer, Ivor Elrifi, purchased 321,423 common shares of the company on NASDAQ at $1.00 per share. The purchase raises his total holding to…